BRIDGE study

  • Research type

    Research Study

  • Full title

    The BRIDGE study- Bronchiectasis Research Involving Databases, Genomics and Endotyping to match the right treatment to the right patient.

  • IRAS ID

    228760

  • Contact name

    James Chalmers

  • Contact email

    jchalmers@dundee.ac.uk

  • Sponsor organisation

    University of Dundee

  • Duration of Study in the UK

    5 years, 0 months, 0 days

  • Research summary

    Bronchiectasis is a lung condition in which the airways are scarred and inflamed with thick mucus. Sufferers often have repeated chest infections and breathing difficulties. There are several different treatment options for people with bronchiectasis but currently, doctors find it hard to understand which treatment suits each person best. This research will focus on choosing the right treatment for the right person for people living with bronchiectasis.
    The aim is to create tests that can help match treatments to people by using state-of-the-art methods like gene sequencing and inflammation measurement technology. These methods will help categorise patients right down to cell level. That means researchers can see which treatment tends to work on which type of person.
    1000 people with bronchiectasis from across Europe will be invited to take part in this research. In the UK Ninewells hospital (Dundee) and the Royal Brompton Hospital (London) will be recruiting. Participants will be asked to take part in a yearly visit to the research centre to donate samples (blood, urine and phlegm), to do a breathing tests to assess the function of their lungs and to answer some questions about their symptoms. This information will have all personal identifiable information (such as name) removed and be entered onto the European Bronchiectasis registry (https://www.bronchiectasis.eu/registry). If the person becomes unwell with a chest infection during the 3 year study they will be invited to donate more samples at that time, either by attending the research centre or by donating surplus clinical samples.
    Eventually, the research aims to show in drug trials that it’s possible to predict which patients will get better.

  • REC name

    London - Chelsea Research Ethics Committee

  • REC reference

    18/LO/1935

  • Date of REC Opinion

    22 Nov 2018

  • REC opinion

    Further Information Favourable Opinion